Page 1 of 2, showing 50 records out of 63 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
63. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. |
Acolbifene |
1997 |
|
62. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long term inhibitory effects of a novel antiestrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. |
Acolbifene |
1997 |
|
61. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. |
Acolbifene |
1997 |
|
60. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. |
Acolbifene |
1997 |
|
59. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. |
Acolbifene |
1997 |
|
58. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. |
Acolbifene |
1997 |
|
57. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. |
Acolbifene |
1997 |
|
56. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. |
Acolbifene |
1997 |
|
55. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. |
Acolbifene |
1997 |
|
54. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. |
Acolbifene |
1998 |
|
53. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. |
Acolbifene |
1998 |
|
52. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. |
Acolbifene |
1998 |
|
51. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. |
Acolbifene |
1998 |
|
50. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. |
Acolbifene |
1998 |
|
49. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. |
Acolbifene |
1998 |
|
48. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. |
Acolbifene |
1998 |
|
47. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. |
Acolbifene |
1998 |
|
46. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology, 139: 111-118. |
Acolbifene |
1998 |
|
45. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. |
Acolbifene |
1998 |
|
44. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Acolbifene |
1999 |
|
43. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. |
Acolbifene |
1999 |
|
42. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. |
Acolbifene |
1999 |
|
41. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. |
Acolbifene |
1999 |
|
40. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. |
Acolbifene |
1999 |
|
39. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. |
Acolbifene |
1999 |
|
38. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. |
Acolbifene |
2000 |
|
37. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
Acolbifene |
2000 |
|
36. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. |
Acolbifene |
2000 |
|
35. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. |
Acolbifene |
2000 |
|
34. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. |
Acolbifene |
2000 |
|
33. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. |
Acolbifene |
2000 |
|
32. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. |
Acolbifene |
2001 |
|
31. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
Acolbifene |
2001 |
|
30. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
Acolbifene |
2001 |
|
29. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
Acolbifene |
2001 |
|
28. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
Acolbifene |
2001 |
|
27. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2003) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068) by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol, 59: 636-45. |
Acolbifene |
2001 |
|
26. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Acolbifene |
2002 |
|
25. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
Acolbifene |
2002 |
|
24. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
Acolbifene |
2002 |
|
23. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
Acolbifene |
2002 |
|
22. Bernardi, F., Stomati, M., Luisi, S., Pieri, M., Labrie, F., Geneazzani, A.R. (2002) Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal β-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertility and Sterility, 77: 1018-1027. |
Acolbifene |
2002 |
|
21. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Labrie, F., Genazzani, A.R. (2002) Genomic and non-genomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. J. Endocrinol, 143: 2052-2061. |
Acolbifene |
2002 |
|
20. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. |
Acolbifene |
2003 |
|
19. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. |
Acolbifene |
2003 |
|
18. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. |
Acolbifene |
2003 |
|
17. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
Acolbifene |
2003 |
|
16. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes. Res., 11: 477-490. |
Acolbifene |
2003 |
|
15. Labrie, F. (2003) Extragonadal synthesis of sex steroïds: Intracrinology. Ann. Endocrinol, 64: 95-107. |
Acolbifene |
2003 |
|
14. Tatchum-Talom, R., Martel, C., Labrie, F., Marette, A. (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. J. of the European Soc. of Cardiology, 57: 535-543. |
Acolbifene |
2003 |